Form 8-K - Current report:
SEC Accession No. 0000950170-25-010199
Filing Date
2025-01-29
Accepted
2025-01-29 07:00:08
Documents
15
Period of Report
2025-01-28
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cgem-20250128.htm   iXBRL 8-K 49982
2 EX-99.1 cgem-ex99_1.htm EX-99.1 37340
3 GRAPHIC img184014297_0.jpg GRAPHIC 15206
4 GRAPHIC img184014297_1.jpg GRAPHIC 12839
5 GRAPHIC img184014297_2.jpg GRAPHIC 17326
  Complete submission text file 0000950170-25-010199.txt   273697

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20250128.xsd EX-101.SCH 24922
17 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20250128_htm.xml XML 4711
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813867811 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39856 | Film No.: 25566642
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)